Trial Profile
A Randomized, Double-blind, Multi-center Phase III Clinical Study to Assess the Efficacy and Safety of Surufatinib Compared to Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Apr 2023
Price :
$35
*
At a glance
- Drugs Surufatinib (Primary)
- Indications Neuroendocrine tumours
- Focus Registrational; Therapeutic Use
- Acronyms SANET-ep
- Sponsors Hutchison MediPharma; HUTCHMED
- 29 Mar 2023 Status changed from active, no longer recruiting to completed.
- 13 Sep 2022 Results from NCT02267967, NCT02588170, NCT02589821; assessing whether radiomics-based machine learning model could predict treatment responses in patients with advanced NET, presented at the 47th European Society for Medical Oncology Congress
- 07 Jun 2022 Results of pooled analysis of two studies ( SANET-p and SANET-ep) assessing surufatinib safety , presented at the 58th Annual Meeting of the American Society of Clinical Oncology.